In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database

Registration

Registration

NCT03479762

Study type

OBSERVATIONAL

Status

COMPLETED

Enrollment

105

Start

2018-04-20

Primary completion

2022-09-12

Lead sponsor

Novo Nordisk A/S

Conditions

Obesity; Overweight

Interventions

DRUG:Liraglutide

Results posted

FALSE

Individual participant data sharing

YES

Secondary identifiers

OTHER:U1111-1185-3276; REGISTRY:EUPAS23369

Registered primary outcomes

• Number of patients with a BMI above or equal to 30 kg/m^2 (Saxenda® only) [Less than 6 months before the date of the first prescription]
• Number of patients with a BMI above or equal to 27 kg/m^2 and below 30 kg/m^2 and 1 or more comorbidities (Saxenda® only) [Less than 6 months before the date of the first prescription]
• Number of patients with a BMI above or equal to 27 kg/m^2 and less than 30 kg/m^2 and no comorbidities (Saxenda® only) [Less than 6 months before the first prescription]
• Number of patients with BMI below 27 kg/m^2 (Saxenda® only) [Less than 6 months before the first prescription]
• Number of patients with less than 5% weight loss and continuing treatment (Saxenda® only) [Week 0 (first prescription) to week 16; week 24]
• Mean weight loss in patients not treated according to stopping rule (Saxenda® only) [Week 0 (first prescription) to week 16; week 24]
• Number of patients with a BMI not measured (Saxenda® only) [Less than 6 months before the first prescription]
• Number of patients with at least 5% weight loss and continuing treatment (Saxenda® only) [Week 16 - week 24]